Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company, on Tuesday, announced encouraging interim results from its ongoing Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma.
The trial met its primary endpoint, demonstrating a statistically significant improvement in 1-year survival rate and median overall survival compared to GnP alone.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.